Provectus Biopharmaceuticals Announces Publication of Australian Compassionate Use Patients Treated with PV-10® Immunotherapy for In-Transit Melanoma Lesions
31. März 2021 07:00 ET
|
Provectus Biopharmaceuticals Inc.
46% complete response of patients at Melanoma Institute AustraliaFifth published study of in-transit melanoma lesion treatment with single-agent PV-1026-50% complete response (52-86% overall response)...
Provectus Biopharmaceuticals Receives Notice of Allowance for Refractory Pediatric Solid Tumor Cancer Monotherapy and Combination Therapy Patent for PV-10® Immunotherapy from United States Patent and Trademark Office
23. März 2021 07:00 ET
|
Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, March 23, 2021 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that the United States Patent and Trademark Office (USPTO) has allowed US patent application 16/412,872,...
Provectus Biopharmaceuticals Announces Discovery of Unique PV-10®-Induced STING Pathway Mechanism for Presentation at American Association for Cancer Research (AACR) 2020 Virtual Annual Meeting II
22. Juni 2020 07:30 ET
|
Provectus Biopharmaceuticals Inc.
PV-10 treatment leads to STING dimerizationResearchers identify potential association of heat shock proteins with STING in PV-10-treated models KNOXVILLE, TN, June 22, 2020 (GLOBE NEWSWIRE) --...
Provectus Announces Presentation of Updated Results from Phase 1B Trial of PV-10® in Combination with KEYTRUDA® for Treatment of Checkpoint-Naïve Advanced Melanoma at SMR 2019 Congress
21. November 2019 09:00 ET
|
Provectus Biopharmaceuticals Inc.
Full accrual of 21 checkpoint-naïve melanoma patientsNo safety concerns identified; no significant overlap of toxicities95% 12-month OS rate; 100% 12-month DSS rate; Median PFS of 11.7 months10% CR...
Article on anti-tumor activity of PV-10 against relapsed and refractory neuroblastoma published in OncoTargets and Therapy
19. Februar 2019 07:30 ET
|
Provectus Biopharmaceuticals Inc.
Provides preclinical proof-of-concept data on efficacy of single-agent PV-10 for treatment of neuroblastomaSupports use of checkpoint inhibitors with PV-10 treatment backbone to further enhance...
PROVECTUS ANNOUNCES PRESENTATION OF UPDATED RESULTS FROM PHASE 1B TRIAL OF PV-10 IN COMBINATION WITH KEYTRUDA® (PEMBROLIZUMAB) FOR TREATMENT OF ADVANCED MELANOMA AT SMR 2018 CONGRESS
25. Oktober 2018 08:00 ET
|
Provectus Biopharmaceuticals Inc.
- Single-agent adverse effect profiles of PV-10 and Keytruda were maintained - 65% overall objective response rate with 9% complete response, via RECIST 1.1 KNOXVILLE, TN, Oct. 25, 2018 ...
PROVECTUS ANNOUNCES PRESENTATION OF DATA FROM METASTATIC UVEAL MELANOMA COHORT OF PHASE 1 STUDY OF PV-10 IN LIVER CANCERS AT SMR 2018 CONGRESS
24. Oktober 2018 16:15 ET
|
Provectus Biopharmaceuticals Inc.
- Assessing adverse event and preliminary efficacy profiles of PV-10 as single-agent and in combination with immune checkpoint inhibition for treatment of liver metastases KNOXVILLE, TN, Oct....
PROVECTUS ANNOUNCES PRESENTATION OF PHASE 1 TRIAL OF PV-10 FOR TREATMENT OF SYMPTOMATIC NEUROENDOCRINE TUMORS METASTATIC TO LIVER AT ESMO 2018 CONGRESS
23. Oktober 2018 09:00 ET
|
Provectus Biopharmaceuticals Inc.
- First cohort of 6 patients enrolled and treated; currently recruiting patients into second cohort KNOXVILLE, TN, Oct. 23, 2018 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that...
PROVECTUS BIOPHARMACEUTICALS CLINICAL TRIALS UPDATE PROVIDED AT EUROPEAN POST-CHICAGO MELANOMA/SKIN CANCER MEETING
10. Juli 2018 08:00 ET
|
Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, July 10, 2018 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that a clinical trials update was provided at the 8th European Post-Chicago Melanoma/Skin Cancer Meeting,...